Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Also called undetected strokes, silent strokes are more common among older individuals, according to the American Health ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...